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When Karim met Nelson Mandela for 
the second time in 2000, he had his 
camera in tow, ready to capture a photo 
of him shaking the hand of his hero. 
Mandela later wrote the foreword to 
Karim and his wife’s book, HIV/AIDS 
in South Africa.
Karim has witnessed the emergence 
and exponential growth of the AIDS 
epidemic in his country, along with the 
concurrent explosion of tuberculosis. To 
reverse the epidemic, he is following 
disease progression, testing treatments 
and prevention strategies (1), and decid-
ing if and how they can be effective in 
resource-limited settings (2). By moni-
toring cytokines and T cell responses in 
the first weeks after infection, Karim has 
found that a more naive CD8  +   T cell 
response is better in the long run than a 
more differentiated response that includes 
a high frequency of memory T 
cells (3, 4). These studies also 
revealed that the initial magni-
tude of HIV-specific, IFN-–
producing cells does not predict 
viral load at one year.
By screening people with 
recent HIV infections, Karim 
has found that the majority of 
cytotoxic T cells recognize 
conserved domains in the Gag 
protein despite differences in 
host genetic backgrounds and 
HIV-1 subtypes. Thus host 
and viral diversity may not constrain the 
ability of a vaccine to elicit a universal 
response (5). Karim leads the Center for 
the AIDS Program of Research in South 
Africa (CAPRISA) and is an epidemiol-
ogy professor at Columbia University in 
New York. And now that he’s helped to 
convince the Howard Hughes Medical 
Institute (HHMI) to establish a new 
research center for HIV and TB in South 
Africa, he will be directing a research 
program there as well.
Who gave you the nickname Slim?
My schoolteacher. Under apartheid in 
South Africa, we had to take Afrikaans 
language classes, which I didn’t like 
because I associated the language 
with racial oppression. My Afri-
kaans teacher once scolded me, “Jy 
dink jy is slim,” which means, “You 
think you are so clever?” It stayed 
with me, as the Afrikaans word 
“slim,” meaning clever, sounds like 
Salim. Plus, I was quite rotund 
then, so the name made [ironic] 
sense and it stuck.
Even as a boy you opposed apartheid?
Yes. I was born in Durban, the 
third  largest city in South Africa, 
and at the age of 10, my family was 
forced to move out of our house 
and to an Indian township 25 kilometers 
south of the city. My mother was active 
in the anti-apartheid movement; she’d go 
to rallies and was part of the passive resist-
ance. And so it sort of rubbed off   on me. 
By the time I went to medical school I 
became involved in human rights and the 
anti-apartheid movement.
After medical school you came to Columbia 
University to do epidemiological research, 
but then returned to South Africa. Why?
In my heart of hearts, I’m South African. 
I feel I have a contribution to make here. 
It’s hard to explain, but this is my country 
and the people here are amazing. It’s the 
adversity that brings out their spirit and 
humanity despite the years of subjuga-
tion and indignity of racism.
WHAT WENT WRONG
How has the political situation in South 
Africa fueled the AIDS epidemic?
I think it’s been a combination of our 
colonial history, the discovery of gold and 
diamonds, and the subsequent building up 
of the apartheid state (1). The migrant 
labor system destroyed family life by turn-
ing black tribesmen into laborers. Hun-
dreds of thousands of black men were 
forced to move near the mines in order to 
work in white South Africa while their 
wives stayed behind in designated rural 
reserves. A man would then see his wife 
once or twice a year, and it became the 
norm for working men to also have what 
was called a town wife, who would see 
several men. This created a situation where 
family life was disrupted and diseases like 
syphilis and HIV could spread rapidly.
Later in the early nineties when it 
became clear that AIDS could be a huge 
heterosexual epidemic in addition to 
being a problem for hemophiliacs and 
gay men, the government was in the 
midst of dealing with what they called 
“swart gevaar,” which literally translates 
to “the black threat.” And the black 
threat was based on the fear that as the 
impoverished black population grew, 
whites were becoming a shrinking mi-
nority in South Africa. So when AIDS 
came around, their perspective was, 
well, if this disease wipes out blacks, 
then that takes care of the swart gevaar. 
And although they didn’t broadcast this, 
the efforts of the apartheid government 
to control HIV were extremely minimal 
and not designed to have an impact.
In August, The Lancet published 
manuscripts assessing the failure of the 
South African government to control the 
AIDS epidemic, and the new South African 
health minister, Aaron Motsoaledi, embraced 
the series. Why was this monumental?
Interaction with government during the 
last few months has been almost surreal 
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because we’ve just been through 10 years 
of having a diffi   cult relationship with a 
minister of health, who saw science as 
something that challenged her perspec-
tives rather than something that she 
could use to impact HIV.
Back in 2000, former president 
Thabo Mbeki had invited me and sev-
eral other scientists to debate whether 
HIV causes AIDS. I participated in the 
debate, but it ended up causing a schism 
between politicians and the science 
community. Mbeki did not appreciate 
that the issue of whether HIV causes 
AIDS is a scientific one and that politi-
cians shouldn’t have been involved in it. 
That period was really the lowest point 
in my life. Despite everything I’d gone 
through under apartheid, this felt some-
how lower. I felt like it undermined 
everything we had been working for.
So after having gone through this 
horrible period and finally having a 
minister who embraced the constructive 
criticisms in The Lancet series, well, I’m 
thrilled. We have to acknowledge that 
we’ve got a big problem on our hands 
before we can fix it.
And you know this new health minister 
personally, correct?
Yes! In fact, yesterday someone asked me 
if I ever imagined that my classmate in 
medical school—the only medical school 
for black students in the country at that 
time—would become the Minister of 
Health, and I said, “Imagine? Are you 
crazy? I never imagined there would be 
freedom in South Africa in my lifetime!”
RESEARCH IN REAL TIME
What will you be doing at HHMI’s new 
center for HIV and TB?
We’ve got a range of studies planned. 
One of them is to learn how much of 
the TB resurgence we’re seeing in pa-
tients with HIV is due to relapse. We 
need to understand relapse and reinfec-
tion because we need to devise strategies 
to stop the rapid spread of TB. Right 
now, we have nearly three quarters of a 
million patients on AIDS treatment. And 
these HIV-positive patients, with and 
without infectious TB, sit for hours in 
long queues in poorly ventilated, crowded 
rooms waiting for medical care—it’s the 
perfect place to spread TB.
Are you involved in any clinical trials?
Several—two on HIV/TB treatment, 
two HIV prevention trials, and one on 
acute HIV infection. In one HIV/TB 
cotreatment trial, we’ve found that inte-
grating TB treatment with antiretroviral 
treatment reduces mortality by 56%, 
potentially saving 10,000 lives in South 
Africa each year. In another trial, we are 
studying acute infection in sex workers. 
Before the trial began, my wife and I 
had been assisting sex workers in an 
intervention program to try and prevent 
HIV with education and condom distri-
bution, so we were familiar with 
the community, enabling us to 
conduct studies with this hard-to-
reach group. We had to screen over 
700 sex workers to fi  nd the 245 
that were HIV-negative. Once they 
volunteered for the study, we did 
everything in our power to con-
vince them to use condoms and 
provided counseling. In fact, they 
appreciated coming into the clinic 
because they received high-quality 
health care from us. Despite this, 
we had an incredibly high inci-
dence rate. And every time a wom-
an was infected, the whole team felt 
that it was our failure. But still, in 
the earliest stages of their infection, 
we studied them in great detail. 
Our main interest was to better under-
stand viral escape. What immune responses 
occur initially? What predicts whether 
you have a low virus set point?
And what have you learned thus far?
We’ve noticed that these women develop 
potent neutralizing antibodies after infec-
tion, but that they only neutralize a narrow 
spectrum of viruses. The problem is that 
there’s high HIV diversity, and as each new 
antibody comes up to suppress the suscep-
tible viral population, viruses 
that are not sensitive to the pre-
vailing neutralizing antibodies 
become dominant. So you’ve 
got evolution in fast-forward, 
leading to viruses that are able 
to escape the immune response. 
We’ve been trying to under-
stand why the body produces 
these antibodies that are so 
potent, yet so narrowly focused, 
by looking at neutralization 
sites on the viral envelope using 
chimeric viruses.
We’ve also been looking at what 
happens to the cells in a woman’s genital 
mucosa before and after infection. We 
want to see if there’s a particular kind of 
immune response in the vagina that sup-
presses the systemic spread of the virus 
and leads to low viral loads. What we’ve 
found so far by looking at the cytokines 
obtained from vaginal washings of 
women pre- and post-infection is that 
you can predict what someone’s HIV 
viral load set point will be. For example, 
we found that increased levels of cytok-
ines IL-6, IL-10, and IL-12 p70 in the 
vagina are associated with HIV infec-
tion. The presence of genital inflamma-
tion not only increases the risk of 
infection but also leads to more severe 
CD4  +   T cell depletion immediately 
after infection (3).
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